CN107533066B - 标记系统，特别是用于杆状病毒表达的亚单位抗原的标记系统 - Google Patents

标记系统，特别是用于杆状病毒表达的亚单位抗原的标记系统 Download PDF

Info

Publication number
CN107533066B
CN107533066B CN201680013955.8A CN201680013955A CN107533066B CN 107533066 B CN107533066 B CN 107533066B CN 201680013955 A CN201680013955 A CN 201680013955A CN 107533066 B CN107533066 B CN 107533066B
Authority
CN
China
Prior art keywords
sequence
ser
leu
ile
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680013955.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107533066A (zh
Inventor
A·V·耶尔
J·R·赫尔曼
M·B·鲁夫
E·M·沃恩
M·L·舍费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Boehringer Ingelheim Animal Health USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc, Boehringer Ingelheim Animal Health USA Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Priority to CN202110085632.2A priority Critical patent/CN113156135B/zh
Publication of CN107533066A publication Critical patent/CN107533066A/zh
Application granted granted Critical
Publication of CN107533066B publication Critical patent/CN107533066B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
CN201680013955.8A 2015-03-05 2016-03-04 标记系统，特别是用于杆状病毒表达的亚单位抗原的标记系统 Active CN107533066B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110085632.2A CN113156135B (zh) 2015-03-05 2016-03-04 用于杆状病毒表达的亚单位抗原的标记系统及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128744P 2015-03-05 2015-03-05
US62/128,744 2015-03-05
PCT/US2016/021003 WO2016141338A2 (en) 2015-03-05 2016-03-04 Marker system, in particular for baculovirus-expressed subunit antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110085632.2A Division CN113156135B (zh) 2015-03-05 2016-03-04 用于杆状病毒表达的亚单位抗原的标记系统及其用途

Publications (2)

Publication Number Publication Date
CN107533066A CN107533066A (zh) 2018-01-02
CN107533066B true CN107533066B (zh) 2021-02-12

Family

ID=55587370

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680013955.8A Active CN107533066B (zh) 2015-03-05 2016-03-04 标记系统，特别是用于杆状病毒表达的亚单位抗原的标记系统
CN202110085632.2A Active CN113156135B (zh) 2015-03-05 2016-03-04 用于杆状病毒表达的亚单位抗原的标记系统及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110085632.2A Active CN113156135B (zh) 2015-03-05 2016-03-04 用于杆状病毒表达的亚单位抗原的标记系统及其用途

Country Status (14)

Country Link
US (2) US10168330B2 (OSRAM)
EP (1) EP3265121B1 (OSRAM)
JP (2) JP6814739B2 (OSRAM)
KR (1) KR102564081B1 (OSRAM)
CN (2) CN107533066B (OSRAM)
AU (1) AU2016226003B2 (OSRAM)
CA (1) CA2977405A1 (OSRAM)
DK (1) DK3265121T3 (OSRAM)
EA (1) EA038831B1 (OSRAM)
ES (1) ES2818148T3 (OSRAM)
HU (1) HUE051827T2 (OSRAM)
MX (1) MX380411B (OSRAM)
PT (1) PT3265121T (OSRAM)
WO (1) WO2016141338A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016226003B2 (en) * 2015-03-05 2021-07-29 Boehringer Ingelheim Animal Health USA Inc. Marker system, in particular for baculovirus-expressed subunit antigens
CN108048476B (zh) 2017-11-21 2020-09-08 浙江迪福润丝生物科技有限公司 一种制备区分免疫和感染动物h9亚型禽流感疫苗株的方法及应用
US10718771B2 (en) 2018-02-09 2020-07-21 Chung Yuan Christian University Recombinant baculoviruses and their uses in detecting arthropod-borne virus
CN109536456B (zh) * 2018-10-26 2021-07-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 识别pcv2病毒样颗粒的单克隆抗体及其在定性及定量检测pcv2病毒样颗粒中的应用
CA3165258A1 (en) 2019-12-18 2021-06-24 Intervet International B.V. Cryptosporidiosis vaccine
JP2023513135A (ja) * 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN116064649B (zh) * 2022-11-24 2023-11-21 南京诺唯赞生物科技股份有限公司 一种在本氏烟草中表达猪瘟病毒e2蛋白的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
HK1052295B (en) * 2000-08-11 2013-06-21 Mmrglobal, Inc. Method and composition for altering a b cell mediated pathology
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) * 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
WO2007053899A1 (en) 2005-11-10 2007-05-18 Diva Solutions Pty Ltd Differentiating therapeutic composition
EP2064229B1 (en) * 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US20100099745A1 (en) * 2006-10-18 2010-04-22 Suryaprakash Sambhara Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
US20090110698A1 (en) 2007-10-31 2009-04-30 Newport Laboratories, Inc. Method of determining vaccine compliance
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
CN102105489A (zh) * 2008-05-29 2011-06-22 美国政府健康与人类服务部秘书处 人c组轮状病毒样颗粒的表达和组装及其应用
CN101884787A (zh) * 2010-07-22 2010-11-17 洛阳普莱柯生物工程有限公司 猪圆环病毒2型亚单位疫苗及其制备方法
RU2015111179A (ru) 2012-08-29 2016-10-20 Интервет Интернэшнл Б.В. Маркерная вакцина
CA2926225A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
AU2016226003B2 (en) * 2015-03-05 2021-07-29 Boehringer Ingelheim Animal Health USA Inc. Marker system, in particular for baculovirus-expressed subunit antigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Development of monoclonal antibody-linked ELISA for sero-diagnosis of vesicular stomatitis virus (VSV-IN) using baculovirus expressed glycoprotein;Chang Hee Kweon et al;《Journal of Virological Methods》;20050801;第130卷;摘要，2.4节 *
水疱性口炎病毒两血清型G蛋白的截短表达和间接ELISA方法的建立;臧京帅等;《中国兽医杂志》;20141231;第50卷(第6期);摘要，第69页左栏，1.10节 *
重组水泡性口炎病毒基质蛋白制备及ELISA检测方法的建立;张世宽等;《上海交通大学学报（农业科学版）》;20140228;第32卷(第1期);摘要，1.6节 *

Also Published As

Publication number Publication date
US10545148B2 (en) 2020-01-28
JP7237913B2 (ja) 2023-03-13
KR102564081B1 (ko) 2023-08-08
AU2016226003B2 (en) 2021-07-29
HUE051827T2 (hu) 2021-03-29
CA2977405A1 (en) 2016-09-09
DK3265121T3 (da) 2020-08-24
US20190154688A1 (en) 2019-05-23
CN113156135A (zh) 2021-07-23
EA038831B1 (ru) 2021-10-26
PT3265121T (pt) 2020-08-31
MX2017011322A (es) 2017-12-07
MX380411B (es) 2025-03-12
WO2016141338A3 (en) 2016-10-06
KR20170122262A (ko) 2017-11-03
WO2016141338A2 (en) 2016-09-09
JP6814739B2 (ja) 2021-01-20
US10168330B2 (en) 2019-01-01
AU2016226003A1 (en) 2017-08-24
JP2021072781A (ja) 2021-05-13
CN113156135B (zh) 2025-01-07
EP3265121A2 (en) 2018-01-10
EA201791957A1 (ru) 2018-03-30
ES2818148T3 (es) 2021-04-09
CN107533066A (zh) 2018-01-02
JP2018516533A (ja) 2018-06-28
EP3265121B1 (en) 2020-06-17
US20160258953A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
JP7237913B2 (ja) マーカー系、特にバキュロウイルス発現サブユニット抗原のためのマーカー系
CN110105436B (zh) 猪圆环病毒3型抗体的elisa检测试剂盒及其制备方法与应用
CN103751773B (zh) 稳定表达猪瘟病毒e0-e1-e2蛋白的重组bhk细胞系及其在制备猪瘟疫苗与诊断试剂中的应用
CN111234036A (zh) 非洲猪瘟病毒p72融合蛋白及其制备方法和应用
CN107531760A (zh) Pcv2 orf2载体平台
AU2009256397B2 (en) Expression and assembly of human group C rotavirus-like particles and uses thereof
Avellaneda et al. Differentiation of infected and vaccinated animals (DIVA) using the NS1 protein of avian influenza virus
CN110845584B (zh) 一种猪瘟病毒囊膜蛋白寡聚蛋白体及其制备方法和应用
CN103539839A (zh) 肠道病毒71型的vp2抗原的中和表位多肽及其用途
CN109563491B (zh) 新颖的副粘病毒及其用途
JP7213507B2 (ja) 組換え豚パルボウイルス抗原タンパク質及びその用途
CN117903300A (zh) 一种a型口蹄疫病毒中和抗体hy1及其制备方法与应用
CN110698542B (zh) 人工改造的猪圆环病毒2型Rep′蛋白、ELISA检测试剂盒及其应用
CN115785286A (zh) 一种猪繁殖与呼吸综合征病毒的融合蛋白及其应用
CN115894718B (zh) 一种非洲猪瘟病毒的抗原表位肽及其应用
CN101886084A (zh) 一种密码子优化的h3ha/xj3-07基因及其核酸疫苗
Eiser Using and Optimizing Drosophila S2 Expression Systems and Affinity Chromatography for Recombinant Antigen Production
CN119192306A (zh) 一种伪狂犬病病毒gD蛋白及其制备方法和应用
CN113173976A (zh) 一种犬流感病毒h3亚型ha蛋白、其制备方法和应用
CN119954965A (zh) 一种包括gp350多肽变体的EBV疫苗及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American Missouri

Applicant after: Bollinger Ingham Animal Health USA Ltd.

Address before: American Missouri

Applicant before: BOEHRINGER INGELHEIM VETMED

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Georgia, USA

Applicant after: Bollinger Ingham Animal Health USA Ltd.

Address before: American Missouri

Applicant before: Bollinger Ingham Animal Health USA Ltd.

GR01 Patent grant
GR01 Patent grant